Diseminación de enterobacterias productoras de carbapenemasas tipo KCP en Venezuela / Spread of carbapenemase-producing Enterobacteriaceae type KCP in Venezuela

La resistencia a carbapenems en la familia Enterobacteriaceae constituye un problema creciente a nivel mundial, siendo el mecanismo de mayor impacto clínico, epidemiológico y microbiológico, la producción de serino-carbapenemasas KPC. Investigar la presencia de carbapenemasas tipo KPC en aislados de Enterobacterias resistentes a carbapenems, provenientes de diversos centros de salud a nivel nacional, durante el período mayo 2010 - junio 2011. En esta investigación se analizaron 91 aislados de Enterobacterias: K pneumoniae (48), E. cloacae (30), E. aerogenes (4), E. coli (2), C. koseri (1), C. freundil (6), con resistencia a carbapenems provenientes de 14 centros de salud. La susceptibilidad antimicrobiana se evaluó siguiendo los criterios de la CLSI 2011. La detección fenotípica de carbapenemasas se realizó mediante el test de Hodge modificado y evaluando la sinergia con el ácido 3-aminofenilborónico 300 µg/disco. Se realizó el Test de Hodge "doble modificado" a los aislados de Enterobacter y Citrobacter. La detección genotípica de carbapenemasas se llevó a cabo mediante PCR utilizando iniciadores para el gen blaKPC. Todos los aislados presentaron a los deinhibición < 22 mm para meropenem y ertapenem. El 95% de los aislados resultaron positivos para el test de Hogde modificado, el test con ácido borónico, y para el gen blaKPC. En el test de Hodge "doble modificado", se observó 100% de positividad. La resistencia a carbapenems mediada por Carbapenemasas KPC, se ha incrementado en los últimos años en el país y el carácter plasmídico de estas enzimas les permite su fácil diseminación entre diversos géneros de Enterobacterias.

Resistance to carbapenems is the family Enterobacteriaceae is a growing problem around the world, being production of KPC serino-carbapenemase, the mayor impact clinical, epidemiological and microbiological mechanism. To investigate the presence of KPC carbapenemases in isolates of Enterobacterias resistant to carbapenems, from various health centers nationwide, during the period May-2010 June 2011. In this study were analyzed 91 Enterobacterias isolates: K. pneumoniae (48), E. cloacae (30), E. aerogenes (4), E. coli (2), C. koseri (1), C. freundii (6), with resistance to carbapenems from 14 health centers. Antimicrobial susceptibility was evaluated according to the criteria of the CLSI 2011. Phenotypic detection of carbapenemases was performed by Modified Hodge Test and it was evaluated the synergy with the 3-aminophenylboronic 300 µg/disc. Test were done with "double Modified" Hodge to Enterobacter and Citrobacter isolates. Genotypic detection of carbapenemases was performed out by using PCR primers for the gene blaKPC. All isolated showed inhibition zones <22 mm for meropenem and ertapemen. The 95% of the isolates were positive for Hogde Modified Test, test with boronic acid, and to blaKPC gene. By performing "Double Modified" Hodge`s essay , we observed a 100% of positivity. Resistance to carbapenems mediated by KPC carbapenemases has increased in the last few years in the country, and plasmidic characterization of these enzymes allows easily dissemination among different genera of Enterobacteriaceae.

Impact of recombinant human growth hormone (RH-RG) treatment on psychiatric, neuropsychological and clinical profiles of GH deficient adults

Background: Untreated GH-deficient adults have a diversity of dysfunctions (e.g. reduced muscle strength, emotional instability during strress, depressive symptons) that may cause deletrious effects on quality of life, and may be positively influenced by recombinant human growth hormone (rh-GH) therapy. Aim: To evaluate the impact of a clinical intervention with rh-GH therapy on GH-deficient adults. Method: The physical, psychiatric and neuropsychological status of 9 GH-deficient adults was determined before and after the administration of rh-GH (0.250 IU/Kg/week) in a double blind placebo-controlled trial for six months. Patients then received rh-GH for a further period of 6 months and their status was re-evaluated. Results: Rh-GH was significant better than placebo at 6th month (p<0.05), producing increased serum Insulin like growth factor-I (IGF-1) levels, reduced body mas index (BMI) and body fat, increased lean body mass and water, reduced wains/hip ratio and increased energy expenditure. The rh-GH therapy was also significantly better than placebo on depressive features as measured by the Hamilton Depression Scale (17-itens) (p=0.0431) and the Beck Depression Inventory (p=0.0431). Neuropsychological evaluations showed significant improvements in measures of Attention: Digit Backward (p=0.035), Verbal Flency (FAS) (p=0.02) and Cognitive Efficiency (WAIS-R tests): Vocabulary (p=0.027), Picture Arrangements (p=0.017), and Comprehension (p=0.01) following rh-GH therapy. Conclusion: The clinical, psychiatric, and neuropsychological impairements of untreated GH-deficient adults can be decresed by rh-GH therapy.